Tectonic Therapeutic, Inc. (NASDAQ:TECX) CEO and Director Alise Reicin filed a Form 4 on October 28, 2026, reporting a stock option exercise transaction dated October 26, 2026.

Key Highlights

  • Transaction: Alise Reicin exercised 10,000 employee stock options (transaction code M) on October 26, 2026, at an exercise price of $2.38 per share.
  • Direct ownership after transaction: Reicin directly beneficially owns 319,078 shares of common stock following the reported transaction.
  • Indirect ownership: An additional 127,030 shares are held indirectly by the Reicin-Boiarsky Family Trust, of which Reicin's spouse is a co-trustee.
  • Remaining derivative position: Following the exercise, Reicin holds 12,957 derivative securities (employee stock options with a $2.38 exercise price) expiring June 27, 2031.
  • Roles: The filing identifies Reicin as both a Director and Chief Executive Officer of Tectonic Therapeutic, Inc.

Reicin Option Exercise and Beneficial Ownership Details at Tectonic Therapeutic

According to the filing, Alise Reicin, serving as Chief Executive Officer and Director of Tectonic Therapeutic, Inc., exercised 10,000 employee stock options on October 26, 2026, at an exercise price of $2.38 per share. The transaction is recorded under code M in Table I (non-derivative securities) and Table II (derivative securities). The filing was signed by Daniel Lochner as Attorney-in-Fact on October 28, 2026.

Following the exercise, the filing reports that Reicin directly owns 319,078 shares of Tectonic Therapeutic common stock. An additional 127,030 shares are held indirectly through the Reicin-Boiarsky Family Trust. The filing states that Reicin's spouse is a co-trustee of the Trust, and that Reicin "may be deemed to have shared voting and dispositive power over the securities held by the Trust." The filing further states that Reicin "disclaims beneficial ownership of the shares held by the Trust except to the extent of her pecuniary interest therein."

Regarding the options exercised, the filing notes they were received in exchange for a stock option to acquire 63,478 shares of common stock pursuant to a merger, as described in a Form 4 filed with the SEC on June 24, 2024. The filing discloses the vesting schedule for the underlying option, with tranches ranging from 1,297 to 4,079 shares vesting between June 2024 and March 2025, subject to continued service. After the exercise of 10,000 options, Reicin retains 12,957 employee stock options at the same $2.38 exercise price, expiring June 27, 2031.

What Was Disclosed

The Form 4 discloses a single option exercise by CEO and Director Alise Reicin on October 26, 2026, covering 10,000 shares of Tectonic Therapeutic common stock at $2.38, with resulting direct ownership of 319,078 shares and indirect trust-held ownership of 127,030 shares.